Health, Beauty And Wellness News: Medline Remedy Contamination, GNC Proxy

  
Generate a summary of this article
Listen to this article
Beta

FDA is advising consumers and health care providers against using Medline Remedy Essentials No-Rinse Cleansing Foam skin care product that was recalled in late March after the agency determined potential contamination with Burkholderia cepacia complex bacteria. The product, marketed by Medline Industries Inc.to health care facilities and providers and to consumers, was recalled by manufacturer Bocchi Laboratories Inc., a subsidiary of Shadow Holdings LLC in Santa Clarita, Calif. (Also see "Jason Mouth Rinse Among Recent Health And Wellness Product Recalls" - HBW Insight, 20 April, 2018.) FDA on May 9 said the recall remains limited to the 4- and 8-ounce packages of the product listed when Bocchi Labs announced the recall, but it is "investigating this matter further to determine whether any additional products or lots may present a risk to consumers."

The agency announced that the Centers for Disease Control and Prevention has reported 10 confirmed cases of B. cepacian infection...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Recalls

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

FSMA Facility, Recall Reinspection Fees Remain On Ice As FDA Heats Up Making Program ‘Feasible’

 
• By Malcolm Spicer

As it has every year since FSMA was passed in 2011, FDA doesn’t plan to impose reinspection fees until it publishes guidance for small businesses to request reductions. FY2025 budget proposal includes plan “to re-structure the fee programs to make it more administratively feasible to operate.”

Durbin Has Tianeptine Reaction: Refiles Bill Requiring Registration Of Dietary Supplements

 
• By Malcolm Spicer

Senate majority whip asks four supplement industry trade groups for “a written plan to work with responsible supplement manufacturers to remove tianeptine and other dangerous or illegal ingredients from the supplement market.”

Insanitary Storage Of FDA-Regulated Products Costs Family Dollar Nearly 42 Million Dollars

 
• By Malcolm Spicer

Nearly 1,300 rodents exterminated at Arkansas warehouse after FDA investigation found lack of climate control in store of food and OTC drugs requiring dry, room-temperature conditions. Firm pleads guilty in largest monetary criminal penalty in US food safety case.

More from Policy & Regulation

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 
• By Malcolm Spicer

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 
• By Malcolm Spicer

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

'Inside Regulatory Affairs' With The Honest Company’s Sharee Crumbey And Monica Sharda

 
• By HBW Insight Team and Nancy Pham

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.